Goal LDL for Patients with Coronary Artery Disease
Primary Treatment Target
- The American College of Cardiology recommends an LDL-C goal of <55 mg/dL for patients with coronary heart disease, representing the most aggressive evidence-based goal 1, 2
- The American Heart Association and American College of Cardiology Foundation suggest treating to LDL-C <70 mg/dL in patients at highest risk, with benefits proportional to the degree of LDL-C reduction 3, 4
Age Considerations
- Age does not modify the LDL-C targets, as older persons have been confirmed to benefit from therapeutic lowering of LDL-C in multiple clinical trials 5, 6
- The evidence supporting aggressive LDL-lowering extends to elderly patients with established atherosclerotic disease 3
Treatment Algorithm to Achieve Goals
- Initiate high-intensity statin therapy to achieve ≥50% LDL-C reduction from baseline 1, 2
- If LDL-C remains ≥70 mg/dL after maximally tolerated statin dose, add ezetimibe 10 mg daily 1, 2
- If LDL-C still >55-70 mg/dL on statin plus ezetimibe, add a PCSK9 inhibitor (evolocumab, alirocumab, or inclisiran) 1, 2
Evidence Supporting Lower Targets
- The PROVE-IT trial demonstrated that achieving median LDL-C of 62 mg/dL with high-dose atorvastatin resulted in a 16% reduction in major cardiovascular events compared to achieving 95 mg/dL 7, 1
- Clinical trials have shown continuous cardiovascular benefit with no lower threshold—patients achieving LDL-C <25 mg/dL demonstrate ongoing risk reduction without safety concerns 1
Secondary Lipid Targets
- If triglycerides ≥200 mg/dL, use non-HDL-C as a secondary target with goal <100 mg/dL (calculated as total cholesterol minus HDL-C) 3, 7, 2
- Consider adding a fibrate or nicotinic acid to LDL-lowering therapy when triglycerides are elevated or HDL-C is low (<40 mg/dL) 7, 5